186 related articles for article (PubMed ID: 36233247)
1. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II.
Witkowski J; Polak S; Rogulski Z; Pawelec D
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233247
[TBL] [Abstract][Full Text] [Related]
2. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III.
Witkowski J; Polak S; Pawelec D; Rogulski Z
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768563
[TBL] [Abstract][Full Text] [Related]
3. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I.
Witkowski J; Polak S; Rogulski Z; Pawelec D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361773
[TBL] [Abstract][Full Text] [Related]
4. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
Ganti A; Yu S; Sharpnack D; Ingalla E; De Bruyn T
Biopharm Drug Dispos; 2023 Aug; 44(4):301-314. PubMed ID: 37102506
[TBL] [Abstract][Full Text] [Related]
6. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
[TBL] [Abstract][Full Text] [Related]
8. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based PK/PD modelling of therapeutic macromolecules.
Thygesen P; Macheras P; Van Peer A
Pharm Res; 2009 Dec; 26(12):2543-50. PubMed ID: 19847627
[TBL] [Abstract][Full Text] [Related]
10. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA
J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
Rostami-Hodjegan A
Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
[TBL] [Abstract][Full Text] [Related]
12. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
[No Abstract] [Full Text] [Related]
13. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma.
Kim HY; Upadhyay PJ; Fahmy A; Liu X; Duong JK; Boddy AV
Clin Pharmacokinet; 2019 Aug; 58(8):1029-1043. PubMed ID: 30868471
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
19. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
[TBL] [Abstract][Full Text] [Related]
20. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
